{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:45:48Z","timestamp":1786121148235,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009051","name":"Ministry of Health of Mexico","doi-asserted-by":"publisher","award":["FPIS2024-INCMN-6892"],"award-info":[{"award-number":["FPIS2024-INCMN-6892"]}],"id":[{"id":"10.13039\/501100009051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020728","name":"Fundaci\u00f3n Gonzalo R\u00edo Arronte","doi-asserted-by":"publisher","award":["S794"],"award-info":[{"award-number":["S794"]}],"id":[{"id":"10.13039\/501100020728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104111","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:49:48Z","timestamp":1780292988000},"page":"104111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T cells for systemic autoimmune diseases"],"prefix":"10.1016","volume":"25","author":[{"given":"Florencia","family":"Rosetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris K.","family":"Madera-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Cenobio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa E.","family":"Aguilar-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C.","family":"Crisp\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0005","first-page":"e1","article-title":"Advanced therapies and regulatory framework in different areas of the globe: past, present, and future","volume":"43","author":"Pimenta","year":"2021","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0010","first-page":"1","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0015","first-page":"12","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0020","first-page":"455","article-title":"CAR T cells and T-cell therapies for Cancer: a translational science review","volume":"331","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0025","first-page":"301","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.autrev.2026.104111_bb0030","first-page":"411","article-title":"Regulation of activated T cell survival in rheumatic autoimmune diseases","volume":"18","author":"Rosetti","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0035","first-page":"856","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0040","first-page":"1","article-title":"RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation","volume":"5","author":"Crespo","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104111_bb0045","first-page":"12","article-title":"Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22","volume":"24","author":"S","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0050","first-page":"210","article-title":"Engineered SH3-derived Sherpabodies function as a modular platform for targeted T-cell immunotherapy","volume":"85","author":"Hern\u00e1ndez-L\u00f3pez","year":"2025","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0055","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0060","first-page":"25","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"38","author":"Mazinani","year":"2022","journal-title":"Biomark Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0065","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.autrev.2026.104111_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0075","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.autrev.2026.104111_bb0080","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-\u03b6 or Fv-\u03b5 receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.autrev.2026.104111_bb0085","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant Immunoreceptors: CD3\u03b6 signaling and CD28 Costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3\u03b6 signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0095","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of Coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.autrev.2026.104111_bb0105","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104111_bb0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.autrev.2026.104111_bb0115","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible Costimulator, CD134, and CD137 in series with signals from the TCR\u03b6 chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0125","first-page":"142","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.autrev.2026.104111_bb0130","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ymthe.2024.02.006","article-title":"Mechanical force determines chimeric antigen receptor microclustering and signaling","volume":"32","author":"Qiu","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0140","first-page":"99","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res"},{"issue":"24","key":"10.1016\/j.autrev.2026.104111_bb0145","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0150","first-page":"12","article-title":"Chimeric antigen receptor T-cell therapy for haematological malignancies: insights from fundamental and translational research to bedside practice","volume":"184","author":"Gr\u00e9goire","year":"2024","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.autrev.2026.104111_bb0155","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"95","key":"10.1016\/j.autrev.2026.104111_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104111_bb0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104111_bb0170","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0180","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel)\u2013an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104111_bb0190","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.autrev.2026.104111_bb0195","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0200","first-page":"15","article-title":"Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia","volume":"139","author":"Frey","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.autrev.2026.104111_bb0205","first-page":"2117","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"380","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104111_bb0210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.autrev.2026.104111_bb0215","first-page":"2893","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"40","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104111_bb0220","first-page":"1595","article-title":"Population cellular kinetics of Lisocabtagene Maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma","volume":"60","author":"Ogasawara","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0225","first-page":"12","article-title":"Regulation of CAR transgene expression to design semiautonomous CAR-T","volume":"25","author":"G\u0142owacki","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0230","first-page":"735","article-title":"B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies","volume":"47","author":"Canny","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0240","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0245","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by Belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104111_bb0250","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104111_bb0260","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104111_bb0265","first-page":"1","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"55","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0270","first-page":"525","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"136","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0275","first-page":"e446","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"4","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0280","first-page":"85","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0285","first-page":"12","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"391","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0290","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104111_bb0295","first-page":"791","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104111_bb0300","first-page":"901","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"82","author":"Merkt","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0305","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1074-7613(04)00112-8","article-title":"Pathogenic roles of B cells in human autoimmunity: insights from the clinic","volume":"20","author":"Martin","year":"2004","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.autrev.2026.104111_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080533","article-title":"Subcutaneous versus intravenous Administration of Rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in Cynomolgus monkeys","volume":"8","author":"Mao","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0315","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104111_bb0320","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0325","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar2789","article-title":"Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis","volume":"11","author":"Rehnberg","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0330","first-page":"12","article-title":"A roadmap for defining \u201cextrafollicular\u201d B cell responses","volume":"54","author":"Eisenbarth","year":"2025","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0335","first-page":"1125","article-title":"Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes","volume":"82","author":"Choi","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.autrev.2026.104111_bb0340","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104111_bb0345","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.cell.2017.07.026","article-title":"Clonal evolution of autoreactive germinal centers","volume":"170","author":"Degn","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0350","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/1074-7613(95)90179-5","article-title":"Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice","volume":"3","author":"Jacobson","year":"1995","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0355","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.1303000","article-title":"Activation of rheumatoid factor\u2013specific B cells is antigen dependent and occurs preferentially outside of germinal centers in the lupus-prone NZM2410 mouse model","volume":"193","author":"Sang","year":"2014","journal-title":"J Immunol"},{"issue":"5589","key":"10.1016\/j.autrev.2026.104111_bb0360","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1126\/science.1073924","article-title":"Evolution of autoantibody responses via somatic Hypermutation outside of germinal centers","volume":"297","author":"William","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.autrev.2026.104111_bb0365","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1084\/jem.20080840","article-title":"ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity","volume":"205","author":"Odegard","year":"2008","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104111_bb0370","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","article-title":"Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA","volume":"52","author":"Soni","year":"2020","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.autrev.2026.104111_bb0375","article-title":"Selective CAR T cell\u2013mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.autrev.2026.104111_bb0380","first-page":"394","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0385","first-page":"258","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"issue":"6297","key":"10.1016\/j.autrev.2026.104111_bb0390","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2026.104111_bb0395","article-title":"Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis","volume":"11(5):eaax1348","author":"Oh","year":"2025","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0400","first-page":"119","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104111_bb0405","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.autrev.2026.104111_bb0410","first-page":"499","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"186","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0415","first-page":"120","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"187","author":"Wang","year":"2025","journal-title":"Cell"},{"issue":"6661","key":"10.1016\/j.autrev.2026.104111_bb0420","first-page":"52","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"381","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.autrev.2026.104111_bb0425","first-page":"453","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"10468","key":"10.1016\/j.autrev.2026.104111_bb0430","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","article-title":"Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells","volume":"30","author":"Hagen","year":"2024","journal-title":"Lancet"},{"issue":"10437","key":"10.1016\/j.autrev.2026.104111_bb0435","first-page":"1627","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Case Reports Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104111_bb0440","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2403743","article-title":"Anti-CD19 CAR T cell in refractory immune thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104111_bb0445","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Case Reports Autoimmun Rev"},{"issue":"15","key":"10.1016\/j.autrev.2026.104111_bb0450","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0455","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104111_bb0460","article-title":"CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation","author":"Pecher","year":"2025","journal-title":"EULAR Rheumatol Open"},{"issue":"2","key":"10.1016\/j.autrev.2026.104111_bb0465","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104111_bb0470","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ard.2025.03.018","article-title":"Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation","volume":"84","author":"Pecher","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104111_bb0475","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"10.1016\/j.autrev.2026.104111_bb0480","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.autrev.2026.104111_bb0485","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease","volume":"6","author":"Par\u00eds-Mu\u00f1oz","year":"2025","journal-title":"Med (Baltimore)"},{"issue":"10","key":"10.1016\/j.autrev.2026.104111_bb0490","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104111_bb0495","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.autrev.2026.104111_bb0500","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:02:01Z","timestamp":1786071721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001254"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104111","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cells for systemic autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104111"}}